SILO

Insider Trades

Name	Value	Action	Price	Current Price
Weisblum EricDirector, Officer: Chief Executive Officer $1.1k2.5k shares BuyDec 15, 2025 $0.42 --
Weisblum EricDirector, Officer: Chief Executive Officer $1.0k2.5k shares BuyDec 15, 2025 $0.41 --
Weisblum EricDirector, Officer: Chief Executive Officer $3651k shares BuyNov 21, 2025 $0.365 --
Weisblum EricDirector, Officer: Chief Executive Officer $3701k shares BuyNov 20, 2025 $0.37 --
Weisblum EricDirector, Officer: Chief Executive Officer $1.8k4.5k shares BuyNov 19, 2025 $0.405 --
Weisblum EricDirector, Officer: Chief Executive Officer $3.0k7.5k shares BuyNov 18, 2025 $0.4033 --

News

globenewswire.comSilo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirementglobenewswire.comJun 18

globenewswire.comSilo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injuryglobenewswire.comMay 7

globenewswire.comSilo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDglobenewswire.comApr 29

globenewswire.comSilo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDglobenewswire.comApr 29

Trade SILO

About Silo Pharma, Inc.

Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.

CEO: Eric Weisblum
IPO Date: Jan 8, 2021

Market Data

Open: $5.81
High: $6.50
Low: $5.68
Volume: 98.7K
Avg Volume: 280.1K
52W High: $15.15
52W Low: $3.32

Valuation

Market Cap: $5.5M
Enterprise Value: $1.6M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-4.7M
Revenue: $72k
Net Income: $-4.2M
Cash: $4.7M
Debt: $0

Events

EarningsSep 2

EPS est. -0.32